Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Regeneron Pharmaceuticals (REGN)

Regeneron Reports Q3 2026 Revenues of $5.1 Billion and GAAP EPS of $18.45

Positive Impact 3 of 5 earnings

Regeneron Pharmaceuticals reported third quarter 2026 total revenues of $5.1 billion, an increase of 36% compared to the same period in 2025. GAAP net income per diluted share rose 35% to $18.45, while non-GAAP diluted EPS grew 70% to $20.07, driven by strong commercial execution and increased Sanofi collaboration revenue.

Key points

  • Total revenues for Q3 2026 increased 36% to $5.1 billion compared to Q3 2025.
  • GAAP diluted EPS increased 35% to $18.45, and non-GAAP diluted EPS increased 70% to $20.07.
  • EYLEA HD U.S. net sales grew 62% to $699 million, and global Libtayo net sales rose 51% to $550 million.
  • Expanded collaboration with Sanofi adding next-generation antibodies, providing a $1.0 billion up-front payment.

The filing

CompanyRegeneron Pharmaceuticals (REGN)
Form8-K, current report
Filed with the SECOct 30, 2026, 6:50 AM ET
Accession number0000872589-26-000032

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Oct 30, 2026, 8:17 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.